

## Special Issue

# Antibiotic Based Strategies for Prevention or Therapy of MDR Pneumonia

### Message from the Guest Editor

Nosocomial infections, such as ventilator-associated pneumonia (VAP), cause serious morbidity in critical care patients. Patients with no previous respiratory problems otherwise may be at increased risk to present with respiratory infections. Moreover, recent exposure to either antibiotics or healthcare settings can predispose a patient to multidrug-resistant (MDR) infections, which are associated with adverse outcomes in the intensive care unit (ICU). Several strategies have been suggested to prevent or manage MDR infections in the ICU. Some of these interventions were associated with reduced pneumonia rates or improvements in the clinical course of infections. However, other studies have reported an increased incidence of MDR following strategies for the prevention of pneumonia. Hence, there is skepticism concerning the role of preventive strategies using antibiotics, topically applied in the bronchial tree, to prevent VAP. In the present Special Issue, we point out strategies for the prevention or therapy of pneumonia caused by MDR, based on the use of antibiotics, either topically applied or used by a systemic route.

### Guest Editor

Prof. Dr. Demosthènes A. Makris  
Intensive Care Unit, University Hospital of Larissa, University of  
Thessaly, 41110 Biopolis Larissa, Greece

### Deadline for manuscript submissions

closed (29 February 2024)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/117385](https://mdpi.com/si/117385)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)